NIKKEI 225
27,686.40 -199.47 (-0.72%) HANG SENG
18,814.82 -626.36 (-3.22%) CRUDE OIL
72.16 -2.09 (-2.81%) GOLD FUTURES
1,801.70 +19.30 (+1.08%) DOW
33,546.27 -50.07 (-0.15%) BTC-GBP
13,783.64 -188.16 (-1.35%)
MEI Pharma, Inc. (0JW9.L)
| Previous close | 0.2819 |
| Open | 0.2552 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.2534 - 0.2598 |
| 52-week range | 0.2534 - 0.2598 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 180,653 |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5190 |
| Earnings date | 08 Feb 2023 - 13 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
SAN DIEGO, December 06, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time. The record date for the adjourned annual meeting continues to be October 13, 2022.
- Business Wire
MEI Pharma Initiates Strategic Realignment
SAN DIEGO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib. As part of the realignment, the company plans to streamline its organization towards the development of two earlier clinical-stage assets, voruciclib a
- Business Wire
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob
